Ovidrel?

Ovidrel is a brand name for choriogonadotropin alfa, a medication used to induce ovulation in women and increase sperm production in men [1].

What is Ovidrel used for?

Ovidrel is prescribed to stimulate the development and release of eggs from the ovary in women undergoing assisted reproductive technology (ART) treatments, such as in vitro fertilization (IVF) [2]. In men, it is used to treat hypogonadotropic hypogonadism, a condition characterized by insufficient production of sex hormones [1].

How does Ovidrel work?

Choriogonadotropin alfa mimics the action of luteinizing hormone (LH), a hormone that plays a crucial role in ovulation in women and testosterone production in men [1][2]. By triggering the LH surge, Ovidrel facilitates the final maturation of ovarian follicles and triggers ovulation. In men, it stimulates the testes to produce androgens like testosterone [1].

When does Ovidrel typically trigger ovulation?

Ovulation usually occurs approximately 34 to 36 hours after Ovidrel injection in women undergoing fertility treatments [2].

What are potential risks or side effects of Ovidrel?

A significant risk associated with Ovidrel use in women is ovarian hyperstimulation syndrome (OHSS), a condition characterized by enlarged ovaries and fluid accumulation in the abdomen. Symptoms can range from mild discomfort to severe illness [2]. Other potential side effects include headache, nausea, and injection site reactions [1].

Are there alternatives to Ovidrel?

For ovulation induction, other medications containing human chorionic gonadotropin (hCG) or recombinant hCG can be used. The choice of medication often depends on physician preference and patient factors [3].

What is the patent status of Ovidrel?

Information on the specific patent expiry dates for Ovidrel (choriogonadotropin alfa) can be found on specialized drug patent tracking websites [4]. These sites track patent filings, expiry dates, and patent litigation that could affect market exclusivity.

Who manufactures Ovidrel?

Ovidrel is manufactured by EMD Serono, a subsidiary of Merck KGaA [5].

How is Ovidrel administered?

Ovidrel is administered via subcutaneous injection [1].

What clinical data supports Ovidrel's use?

Clinical trials have demonstrated the efficacy of choriogonadotropin alfa in inducing ovulation and supporting pregnancy in women undergoing ART, as well as in improving sperm parameters in men with hypogonadotropic hypogonadism [1][2].

What do patients ask about Ovidrel?

Patients often inquire about the timing of ovulation after injection, the potential for multiple births, and the management of OHSS. Understanding the injection procedure and potential side effects are also common concerns [2].

Sources

1. https://www.drugpatentwatch.com/drug/ovidrel
2. https://www.drugpatentwatch.com/drug/choriogonadotropin-alfa
3. https://www.drugpatentwatch.com/drugs/infertility-drugs
4. https://www.drugpatentwatch.com/
5. https://www.emdserono.com/